Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease
复制标题
DOI：
10.1016/s0304-3940(01)02214-5
复制
发表时间：
2001-10-26
影响因子：
2.5
通讯作者：
Sato, C
中科院分区：
文献类型：
--
作者：
Abe, T;Tohgi, H;Sato, C
为了探讨一氧化氮（NO）介导的神经元死亡在衰老和阿尔茨海默病（AD）中的意义，测定了神经正常对照和AD患者脑脊液中内源性NO合成酶抑制剂不对称二甲基精氨酸（ADMA）的浓度。ADMA浓度随年龄的增长而显著降低，而精氨酸浓度不变。与同龄对照组相比，AD患者ADMA浓度显著降低（-48%,P = 0.0001），且ADMA浓度随认知功能下降而显著降低（r(s) = 0.58, P < 0.05），而精氨酸浓度无变化。这些结果提示ADMA可能在脑老化和AD中调节NO合成中发挥重要作用。(C) 2001爱思唯尔科学爱尔兰有限公司版权所有。
To investigate the significance of nitric oxide (NO) -mediated neuron death in aging and Alzheimer's disease (AD), the concentration of asymmetrical dimethylarginine (ADMA), an endogenous NO synthase inhibitor, in the cerebrospinal fluid was determined in neurologically normal controls and patients with AD. The ADMA concentration significantly decreased with age, whereas the arginine concentration was unaltered. In patients with AD, the ADMA concentration was significantly decreased, compared with controls of a similar age (-48%, P = 0.0001), and it significantly decreased with decreasing cognitive functions (r(s) = 0.58, P < 0.05), whereas the arginine concentration did not change. These findings suggest that ADMA may play an important role in regulating NO synthesis in brain aging and AD. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.